scholarly journals ТHE EFFICIENCY AND SAFETY OF CALCINEURIN INHIBITORS (TACROLIMUS) IN ATOPIC DERMATITIS AND OTHER DERMATOLOGICAL DISEASES

2011 ◽  
Vol 8 (2) ◽  
pp. 89-95
Author(s):  
S A Ochelenko ◽  
K N Monakhov ◽  
S A Ochelenko ◽  
K N Monakhov
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Effects ◽  
Alopecia Areata ◽  
Clinical Effect ◽  
High Efficiency ◽  
Skin Diseases ◽  
Calcineurin Inhibitors ◽  
Dermatological Diseases ◽  
Positive Effects ◽  
Topical Corticosteroids

The problems of clinical efficiency and safety of application of tacrolimus (Protopik) at various skin diseases are discussed in this review. High efficiency of this drug, allows to use it in treatment of different dermatosis. The clinical effect is comparable with topical corticosteroids, and the rate of adverse effects is lower. It is possible to use long applications of calcineurin inhibitors in patients with resistant forms of atopic dermatitis. Positive effects of application of tacrolimus in vitiligo, balanitis, alopecia areata etc. are described.

Calcineurin Inhibitors: A Novel Approach to Canine Atopic Dermatitis

2005 ◽  
Vol 41 (2) ◽  
pp. 92-97 ◽  
Author(s):  
Rosanna Marsella
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Effects ◽  
Mechanism Of Action ◽  
Broad Spectrum ◽  
Skin Diseases ◽  
Calcineurin Inhibitors ◽  
Relevant Information ◽  
Novel Approach ◽  
Allergic Skin ◽  
Traditional Therapies

The introduction of calcineurin inhibitors represents a major addition to the armamentarium of drugs available to veterinary clinicians for the management of allergic skin diseases. Both cyclosporine and tacrolimus have been proven to be well tolerated and effective for the treatment of atopic dermatitis in dogs. Although broad spectrum in their mechanism of action, they lack the major adverse effects of glucocorticoids and provide an appealing alternative to traditional therapies. The purposes of this article are to review clinically relevant information regarding these agents and to provide tips for maximizing the benefit obtained from these therapies.

scholarly journals Itch in Atopic Dermatitis – What Is New?

2021 ◽  
Vol 8 ◽  
Author(s):  
Franz J. Legat
Keyword(s):  
Atopic Dermatitis ◽  
Intracellular Signaling ◽  
Sleep Disturbances ◽  
Skin Diseases ◽  
Immunosuppressive Agents ◽  
Calcineurin Inhibitors ◽  
Inflammatory Skin Diseases ◽  
New Era ◽  
Short And Long Term ◽  
Chronic Pruritus

Atopic dermatitis (AD) is among the most frequent inflammatory skin diseases in humans, affecting up to 20% of children and 10% of adults in higher income countries. Chronic pruritus is a disease-defining symptom of AD, representing the most burdensome symptom for patients. Severe chronic pruritus causes significant sleep disturbances and impaired quality of life, as well as increased anxiety, depression and suicidal behavior. Until recently, skin care, topical corticosteroids, and calcineurin-inhibitors were primarily used to treat mild to moderate AD, while phototherapy and immunosuppressive agents such as corticosteroids, cyclosporine, and methotrexate were used to treat patients with moderate to severe AD. The potential short- and long-term adverse events associated with these treatments or their insufficient therapeutic efficacy limited their use in controlling pruritus and eczema in AD patients over longer periods of time. As our understanding of AD pathophysiology has improved and new systemic and topical treatments have appeared on the market, targeting specific cytokines, receptors, or their intracellular signaling, a new era in atopic dermatitis and pruritus therapy has begun. This review highlights new developments in AD treatment, placing a specific focus on their anti-pruritic effects.

Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis

2019 ◽  
Vol 23 (3_suppl) ◽  
pp. 3S-13S ◽  
Author(s):  
Charles W. Lynde ◽  
James Bergman ◽  
Loretta Fiorillo ◽  
Lyn Guenther ◽  
Jill Keddy-Grant ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Calcineurin Inhibitors ◽  
Skin Condition ◽  
Future Research ◽  
Barrier Dysfunction ◽  
Psychosocial Burden ◽  
Epidermal Barrier ◽  
Topical Corticosteroids ◽  
Topical Calcineurin Inhibitors ◽  
Inflammatory Conditions

Atopic dermatitis (AD) is a chronic inflammatory skin condition, also referred to as atopic eczema, that is identified by itching and recurrent eczematous lesions. It often starts in infancy where it affects up to 20% of children but is also highly prevalent in adults. AD inflicts a significant psychosocial burden on patients and their families and increases the risk of other immune-mediated inflammatory conditions, such as asthma and allergic rhinitis, food allergy, and mental health disorders. It is a lifelong condition associated with epidermal barrier dysfunction and altered immune function. Through the use of emollients and anti-inflammatory agents, current prevention and treatment therapies attempt to restore epidermal barrier function. Acute flares are treated with topical corticosteroids. Topical calcineurin inhibitors (TCIs) and topical corticosteroids (TCSs) are used for proactive treatment to prevent remission. There remains a need and opportunity to improve AD care through future research directed toward an improved understanding of the heterogeneity of the disease and its subtypes, the role of autoimmunity in its pathogenesis, the mechanisms behind disease-associated itch and response to specific allergens, and the comparative effectiveness and safety of therapies.

scholarly journals LONG-TERM CONTROL OF SKIN ALLERGIC INFLAMMATION IN ATOPIC DERMATITIS PATIENTS

2014 ◽  
Vol 11 (3) ◽  
pp. 30-36
Author(s):  
O G ELISYUTINA ◽  
E S FEDENKO
Keyword(s):  
Atopic Dermatitis ◽  
Topical Treatment ◽  
Allergic Inflammation ◽  
Calcineurin Inhibitors ◽  
Intermittent Treatment ◽  
Topical Corticosteroids ◽  
Topical Calcineurin Inhibitors ◽  
Proactive Therapy

Modern approaches to topical treatment of atopic dermatitis (ad) are presented in the review. the application of different proactive therapy patterns like topical corticosteroids intermittent treatment and topical calcineurin inhibitors as antirecurrent therapy of ad patients are discussed.

scholarly journals The role of nutrition in the prevention and therapy of selected skin diseases

2021 ◽  
Vol 10 (4) ◽  
pp. 175-179
Author(s):  
Magdalena Daszkiewicz ◽  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Diseases ◽  
The Body ◽  
Unhealthy Lifestyle ◽  
Dermatological Diseases ◽  
Poor Diet ◽  
Current State ◽  
Prevention And Therapy

Nowadays it is known that many dermatological diseases are associated with a poor diet and unhealthy lifestyle. Some nutrients can exacerbate the disease, while others aid in their treatment. The aim of the study was to present the current state of knowledge on the influence of nutrients on the course of skin diseases such as acne, atopic dermatitis and urticaria. Providing the body with the necessary ingredients and eliminating those that favor the development or worsening of symptoms are an important element in the treatment of many skin diseases.

scholarly journals Different Approaches to Atopic Dermatitis by Allergists, Dermatologists, and Pediatricians

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Suzieni Padoin Zuccolo de Bortoli ◽  
Herberto José Chong Neto ◽  
Nelson Augusto Rosário Filho
Keyword(s):  
Atopic Dermatitis ◽  
Environmental Control ◽  
Calcineurin Inhibitors ◽  
Cross Sectional Study ◽  
Inflammatory Skin Disease ◽  
Cross Sectional ◽  
Medical Specialties ◽  
Topical Corticosteroids ◽  
Diagnostic Approaches ◽  
And Control

Objectives. Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease, with a vast drug arsenal and guidelines available for its management and diagnosis and different medical specialties engaged in providing care. This study aimed to outline the therapeutic and diagnostic approaches to the AD of allergists, dermatologists, and pediatricians and verify whether they are compliant with the guidelines. Methods. A cross-sectional study using an electronic questionnaire administered through the SurveyMonkey® platform was disclosed by participating medical societies to their medical associates. Results. Of the 1,473 participating physicians, the use of moisturizers as part of AD treatment was observed among pediatricians (91.9%), dermatologists (97.5%), and allergists (100%; p = 0.07 ). The preference for the use of new emollients was lower among pediatricians (57%) than dermatologists (75.9%) and allergists (71.4%; p < 0.001 ). The prevalence of wet-wrap therapy was lower among dermatologists (16.3%) than allergists (51%; p < 0.001 ). The recommendation of proactive treatment with topical corticosteroids was more frequently reported by allergists (65.3%) than pediatricians (43.3%) and dermatologists (40.8%; p < 0.001 ), and the same trend was observed in relation to proactive treatment using calcineurin inhibitors. The use of oral anti-histamines to control pruritus was mainly considered by pediatricians (69.2%) and dermatologists (59.2% p < 0.001 ). Clinical experience with systemic immunomodulating agents was greater among allergists (77.5%) and dermatologists (60.8%; p < 0.001 ), with cyclosporine being the most cited systemic immunomodulating agent. Environmental control of aeroallergens was recommended by pediatricians (89.8%), dermatologists (86.9%), and allergists (100%; p = 0.01 ). Conclusion. There were differences in the therapeutic and diagnostic approaches to AD used by allergists, dermatologists, and pediatricians and those recommended by the guidelines, especially regarding the use of wet-wrap therapy, proactive treatment with topical corticosteroids or calcineurin inhibitors, prescription of anti-histamines, recommendation of phototherapy, and control of aeroallergens.

Sign in / Sign up

Export Citation Format

Share Document